4.7 Article

Fra-2 regulates B cell development by enhancing IRF4 and Foxo1 transcription

期刊

JOURNAL OF EXPERIMENTAL MEDICINE
卷 214, 期 7, 页码 2059-2071

出版社

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20160514

关键词

-

资金

  1. Deutsche Forschungsgemeinschaft [CRC1181, SPP1468, BO3811/1-1, WE 4892/3-1]

向作者/读者索取更多资源

The role of AP-1 transcription factors in early B cell development and function is still incompletely characterized. Here we address the role of Fra-2 in B cell differentiation. Deletion of Fra-2 leads to impaired B cell proliferation in the bone marrow. In addition, IL-7-stimulated pro-B cell cultures revealed a reduced differentiation from large pre-B cells to small B cells and immature B cells. Gene profiling and chromatin immunoprecipitation sequencing analyses unraveled a transcriptional reduction of the transcription factors Foxo1, Irf4, Ikaros, and Aiolos in Fra-2-deficient B cells. Moreover, expression of IL7R alpha and Rag 1/2, downstream targets of Irf4 and Foxo1, were also reduced in the absence of Fra-2. Pro-B cell proliferation and small pre-B cell differentiation were fully rescued by expression of Foxo1 and Irf4 in Fra-2-deficient pro-B cells. Hence, Fra-2 is a key upstream regulator of Foxo1 and Irf4 expression and influences proliferation and differentiation of B cells at multiple stages.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Rheumatology

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)

Laura C. Coates, Laure Gossec, Elke Theander, Paul Bergmans, Marlies Neuhold, Chetan S. Karyekar, May Shawi, Wim Noel, Georg Schett, Iain B. McInnes

Summary: The study demonstrated that guselkumab significantly improved joint and skin manifestations as well as physical function in patients with TNFi-IR PsA. A higher proportion of patients in the guselkumab group achieved ACR20 and other key secondary endpoints compared to the placebo group, with 58% of ACR20 response in the guselkumab group at week 48.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Letter Rheumatology

Higher serum levels of short-chain fatty acids are associated with non-progression to arthritis in individuals at increased risk of RA

Klara Martinsson, Kerstin Durholz, Georg Schett, Mario M. Zaiss, Alf Kastbom

ANNALS OF THE RHEUMATIC DISEASES (2022)

Review Rheumatology

Concepts of Entheseal Pain

Enrico De Lorenzis, Gerlando Natalello, David Simon, Georg Schett, Maria Antonietta D'Agostino

Summary: Pain is the main symptom in entheseal diseases. Eicosanoids, cytokines, and neuropeptides released during inflammation and mechanical challenge stimulate nerves and blood vessels to invade the enthesis. Nociceptive pseudounipolar neurons support this process by releasing neurotransmitters that induce neovascularization and sensitization, which may explain the dissociation between pain and imaging findings.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Endocrinology & Metabolism

Chronic Systemic Infection of Mice with Leishmania infantum Leads to Increased Bone Mass

Chaobo Lai, Jennifer Heinemann, Ulrike Schleicher, Georg Schett, Christian Bogdan, Aline Bozec, Didier Soulat

Summary: Chronic infection with Leishmania increases bone mass by inducing bone formation and impairing osteoclast differentiation and function.

JOURNAL OF BONE AND MINERAL RESEARCH (2023)

Article Rheumatology

Contribution of Type H Blood Vessels to Pathologic Osteogenesis and Inflammation in an Experimental Spondyloarthritis Model

Merlijn H. Kaaij, Jan Piet van Hamburg, Charlotte C. N. van Rooijen, Anika Grueneboom, Yik Y. Kan, Desiree Pots, Georg Schett, Leo J. van Ruijven, Leonie M. van Duivenvoorde, Leonie F. A. Huitema, Dominique L. P. Baeten, Sander W. Tas

Summary: This study found that the increase of type H vessels in a transgenic mouse model is closely related to pathologic osteogenesis. This finding provides new insights into the pathophysiology of ankylosing spondylitis and may offer a novel target for intervention.

ARTHRITIS & RHEUMATOLOGY (2023)

Editorial Material Rheumatology

Clinical Images: Increased bone metabolism in secondary hyperparathyroidism

Larissa Valor-Mendez, Armin Atzinger, Petra Reis, Bernhard Manger, Georg Schett

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Baricitinib Improves Bone Properties and Biomechanics in Patients With Rheumatoid Arthritis: Results of the Prospective Interventional BARE BONE Trial

David Simon, Ioanna Minopoulou, Stephan Kemenes, Sara Bayat, Koray Tascilar, Melek Yalcin Mutlu, Larissa Valor-Mendez, Gerhard Kroenke, Axel J. Hueber, Georg Schett, Arnd Kleyer

Summary: Objective. This study aimed to evaluate the effect of Janus kinase inhibition (JAKi) through baricitinib (BARI) on bone properties and synovial inflammation in rheumatoid arthritis (RA) patients. Results showed that BARI therapy significantly improved disease activity, synovial inflammation, and bone mass of RA patients, with no new safety signals observed.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Amelioration of Fibrotic Remodeling of Human 3-Dimensional Full-Thickness Skin by Transglutamase 2 Inhibition

Xiang Zhou, Thuong Trinh-Minh, Alexandru-Emil Matei, Andrea-Hermina Gyoerfi, Xuezhi Hong, Christina Bergmann, Georg Schett, John Atkinson, Rowann Bowcutt, Jessal Patel, Timothy S. Johnson, Joerg H. W. Distler

Summary: In this study, increased expression and activity of TG2 were observed in systemic sclerosis (SSc) patients. Inhibition of TG2 in dermal fibroblasts resulted in reduced fibrosis, suggesting that targeting TG2 may be a potential antifibrotic approach in SSc.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies

Dennis McGonagle, Iain B. B. McInnes, Atul Deodhar, Georg Schett, May Shawi, Soumya D. D. Chakravarty, Alexa P. P. Kollmeier, Xie L. L. Xu, Shihong Sheng, Stephen Xu, Christopher T. T. Ritchlin, Proton Rahman, Phillip J. J. Mease

Summary: The study found that a higher proportion of patients treated with guselkumab achieved resolution of dactylitis, and this resolution was associated with other important clinical outcomes.

ACR OPEN RHEUMATOLOGY (2023)

Article Endocrinology & Metabolism

Opportunistic Screening With CT: Comparison of Phantomless BMD Calibration Methods

Stefan Bartenschlager, Alexander Cavallaro, Tobias Pogarell, Oliver Chaudry, Michael Uder, Sundeep Khosla, Georg Schett, Klaus Engelke

Summary: Opportunistic screening is a promising technique for identifying individuals at high risk for osteoporotic fracture using CT scans. This study compared the performance of four existing phantomless calibration methods and found that precalibrated phantomless calibration methods performed well.

JOURNAL OF BONE AND MINERAL RESEARCH (2023)

Review Rheumatology

Immune mechanisms of depression in rheumatoid arthritis

James Brock, Neil Basu, Johannes C. M. Schlachetzki, Georg Schett, Iain B. Mcinnes, Jonathan Cavanagh

Summary: Depression is a common comorbidity in rheumatoid arthritis, and shared immune mechanisms link the two conditions. This Review explores potential peripheral and central interactions between the immune system and brain, the understanding of which could aid in the development of novel therapeutics.

NATURE REVIEWS RHEUMATOLOGY (2023)

Article Rheumatology

The bone marrow side of axial spondyloarthritis

Daniele Mauro, Saviana Gandolfo, Enrico Tirri, Georg Schett, Walter P. P. Maksymowych, Francesco Ciccia

Summary: This perspective discusses the evidence that supports a bone marrow origin for spondyloarthritis, rather than an entheseal origin. Focusing on immune cells and dysfunction in the bone marrow niche could alter the therapeutic approach to spondyloarthritis.

NATURE REVIEWS RHEUMATOLOGY (2023)

Article Rheumatology

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

Georg Schett, Warner Chen, Sheng Gao, Soumya D. Chakravarty, May Shawi, Frederic Lavie, Miriam Zimmermann, Mohamed Sharaf, Laura C. Coates, Stefan Siebert

Summary: In the COSMOS trial, guselkumab demonstrated efficacy in treating TNFi-IR PsA patients by reducing levels of effector cytokines associated with the IL-23/IL-17 pathway.

ARTHRITIS RESEARCH & THERAPY (2023)

Article Rheumatology

Student-led clinics and ePROs to accelerate diagnosis and treatment of patients with axial spondyloarthritis: results from a prospective pilot study

Sophie von Rohr, Johannes Knitza, Manuel Grahammer, Marc Schmalzing, Sebastian Kuhn, Georg Schett, Andreas Ramming, Hannah Labinsky

Summary: The study aimed to investigate the use of student-led clinics and electronic patient-reported outcomes (ePROs) for the diagnosis and treatment of patients with axial spondyloarthritis (axSpA). The results showed that student-led clinics significantly accelerated patient appointments and NSAID therapy start, and completed the diagnostic workup for all patients. The electronic and paper-administered BASDAI questionnaires showed good correlation. Both student-led clinics and ePRO monitoring were well accepted by patients.

RHEUMATOLOGY INTERNATIONAL (2023)

Article Rheumatology

Real-world usage of digital health applications (DiGA) in rheumatology: results from a German patient survey

Hannah Labinsky, Latika Gupta, Maria Gabriella Raimondo, Georg Schett, Johannes Knitza

Summary: Mobile health applications and digital therapeutics aim to improve patient care, but real-world data on their efficacy is scarce. This study evaluated the adherence, acceptance, and efficacy of digital therapeutics in a rheumatology setting. Results showed high acceptance of digital therapeutics in rheumatic disease patients, but challenges in onboarding and adherence were observed. A subgroup of patients using exercise-based digital therapeutics reported symptom improvement.

RHEUMATOLOGY INTERNATIONAL (2023)

暂无数据